Adam Hansard
CIK 1805556 · Chief Commercial Officer · last filed 2024-03-18
Adam Hansard is a Chief Commercial Officer who has filed 15 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for APLT, was dated May 17, 2024. Across all open-market trades the lifetime net is −$348.8K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
APLT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
545 5TH AVENUE, SUITE 1400
NEW YORK, NY 10017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Applied Therapeutics, Inc. (APLT) Delisted | Chief Commercial Officer | 732,919 | $0.10 | $75.5K | -$348.8K | 13 | 2024-03-18 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-17 | Applied Therapeutics, Inc. (APLT) Delisted | Notice (144) | −115,777 | -$467.7K | EDGAR |
| 2024-05-16 | Applied Therapeutics, Inc. (APLT) Delisted | Notice (144) | −179,425 | -$753.6K | EDGAR |
| 2024-03-18 | Applied Therapeutics, Inc. (APLT) Delisted | Sell (S) | −48,871 | -$263.4K | EDGAR |
| 2023-12-22 | Applied Therapeutics, Inc. (APLT) Delisted | Grant (A) | +400,000 | $0 | EDGAR |
| 2023-12-01 | Applied Therapeutics, Inc. (APLT) Delisted | Sell (S) | −965 | -$1.9K | EDGAR |
| 2023-09-29 | Applied Therapeutics, Inc. (APLT) Delisted | Sell (S) | −9,720 | -$26.2K | EDGAR |
| 2023-01-13 | Applied Therapeutics, Inc. (APLT) Delisted | Mixed | +295,505 | -$4.1K | EDGAR |
| 2022-08-04 | Applied Therapeutics, Inc. (APLT) Delisted | Disp (D) | — | $0 | EDGAR |
| 2022-04-15 | Applied Therapeutics, Inc. (APLT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-11 | Applied Therapeutics, Inc. (APLT) Delisted | Grant (A) | +31,700 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.